Meta-analysis of the effects of statins on perioperative outcomes in vascular and endovascular surgery  by Antoniou, George A. et al.
From
U
Auth
Add
Rep
R
(e
The
to
m
0741
Cop
httpMeta-analysis of the effects of statins on
perioperative outcomes in vascular and
endovascular surgery
George A. Antoniou, MD, PhD, MSc, FEBVS, Shahin Hajibandeh, MBChB, Shahab Hajibandeh, MBChB,
Srinivasa Rao Vallabhaneni, MD, FRCS, FEBVS, John A. Brennan, MD, FRCS, and
Francesco Torella, MD, FRCS, Liverpool, United Kingdom
Background: Compelling evidence from large randomized trials demonstrates the salutary effects of statins on primary and
secondary protection from adverse cardiovascular events in high-risk populations. Our objective was to investigate the
role of perioperative statin therapy in noncardiac vascular and endovascular surgery.
Methods: Electronic information sources were systematically searched to identify studies comparing outcomes after
noncardiac surgical or endovascular arterial reconstruction in patients who were and were not taking statin in the peri-
operative or peri-interventional period. The Cochrane Collaboration’s tool and the Newcastle-Ottawa scale were used to
assess the methodologic quality and risk of bias of the selected studies. Random-effects models were applied to calculate
pooled outcome data.
Results: Four randomized controlled trials and 20 observational cohort or case-control studies were selected for analysis.
The randomized studies enrolled 675 patients, and the observational studies enrolled 22,861 patients. Statin therapy was
associated with a signiﬁcantly lower risk of all-cause mortality (odds ratio [OR], 0.54; 95% CI, [CI], 0.38-0.78),
myocardial infarction (OR, 0.62; 95% CI, 0.45-0.87), stroke (OR, 0.51; 95% CI, 0.39-0.67), and the composite of
myocardial infarction, stroke, and death (OR, 0.45; 95% CI, 0.29-0.70). No signiﬁcant differences in cardiovascular
mortality (OR, 0.82; 95% CI, 0.41-1.63) and the incidence of kidney injury (OR, 0.90; 95% CI, 0.58-1.39) between the
groups were identiﬁed.
Conclusions: Our analysis demonstrated that statin therapy is beneﬁcial in improving operative and interventional out-
comes and should be considered as part of the optimization strategy for prevention of adverse cardiovascular and cere-
brovascular events and death. (J Vasc Surg 2015;61:519-32.)Patients with arterial disease undergoing noncardiac
vascular surgery constitute a high-risk population. A sys-
temic atherosclerotic process affecting different organ
systems, such as the coronary, cerebral, and renal circula-
tion, is frequently encountered in these patients. This is re-
ﬂected in the frequent existence of multiple comorbidities
and an unfavorable cardiovascular risk proﬁle in this group
of patients, which along with the frequent complexity
of vascular surgery, increase the perioperative risk of
morbidity and mortality.1 The consequences of such events
have signiﬁcant health care implications.2
Despite advances in perioperative care, optimization stra-
tegies are required to reduce the operative risk in the vascular
patient. In this context, 3-hydroxy-3-methylglutarylthe Liverpool Vascular and Endovascular Service, Royal Liverpool
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://dx.doi.org/10.1016/j.jvs.2014.10.021coenzyme A reductase inhibitors (statins) have been intro-
duced as effective pharmacologic agents. Statins, along with
their lipid-lowering properties, exert numerous beneﬁcial ac-
tions, termed the “pleiotropic effects.”3,4 Compelling evi-
dence from large randomized trials supports the salutary
effects of statins on primary and secondary protection from
adverse cardiovascular events in high-risk populations, such
as those with peripheral and coronary arterial disease.5-9
Furthermore, a growing interest in using statins perio-
peratively to mitigate the risk of unfavorable cardiac events
is demonstrated in the increasing number of studies investi-
gating their protective role in noncardiac and cardiac
surgery.10-12 Although previous systematic reviews and
meta-analyses have indicated that perioperative statin use re-
duces postoperative cardiac complications and mortality, they
are limited by their generalizability because they have
included patients undergoing a wide range of surgical proce-
dures. Speciﬁc evidence supporting the protective effects of
statins in vascular and endovascular surgery is inconclu-
sive.13,14 Our objective was to undertake a comprehensive re-
view of the literature and investigate the role of perioperative
statin use in noncardiac vascular and endovascular surgery.
METHODS
Design and study selection. The criteria for study se-
lection, methods of analysis, and investigated outcomes519
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This protocol was not registered at the International Pro-
spective Register of Systematic Reviews. The review con-
formed to the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) statement
standards.15
We selected randomized controlled trials and observa-
tional cohort or case-control studies investigating the ef-
fects of statins on perioperative or peri-interventional
outcomes. Participants of any age and gender diagnosed
with arterial disease affecting any anatomic area, except
the intracranial or coronary circulation, were considered.
Patients with occlusive or aneurysmal arterial disease were
eligible. An eligible study deﬁned groups of patients under-
going any noncardiac/intracerebral surgical or endovascu-
lar arterial reconstruction allocated to or receiving statin
therapy and those assigned to placebo or not receiving a
statin at the time of intervention.
The list of interventions was not exhaustive and
included bypass with any conduit (prosthetic, autologous,
or heterologous), endarterectomy with or without patch
arterioplasty, endoaneurysmorrhaphy, balloon angioplasty
with or without stenting with any kind of stent (bare,
covered, drug-eluting, bioabsorbable, open-cell or closed-
cell), stent graft exclusion of the aneurysm, atherectomy,
cryoplasty, or any combinations of these, including hybrid
surgical and endovascular reconstruction.
Primary outcome parameters were deﬁned as mortality
from any cause and cardiovascular mortality. Renal impair-
ment, myocardial infarction, stroke, and the composite of
myocardial infarction, stroke, and death, comprised the
secondary outcome end points.
Literature search strategy. Studies were identiﬁed by
searching electronic bibliographic databases and scanning
reference lists of articles. The search was applied to the Na-
tional Library of Medicine’s MEDLINE database using the
PubMed Web-based search engine. Search dates were from
1966 to the present date, with the last search run on May
11, 2014. Search terms, medical subject headings (MeSH),
and limits were: “hydroxymethylglutaryl-CoA Reductase
Inhibitors” (MeSH), “HMG-CoA reductase inhibitors,”
“statin,” “statins,” “lipid-lowering therapy,” “lipid-lowering
treatment,” “lipid pharmacotherapy,” “non-cardiac vascular
surgery,” “vascular surgery,” “vascular surgical procedures”
(MeSH), “peripheral arterial disease” (MeSH), “endarter-
ectomy, carotid” (MeSH), “aortic aneurysm, abdominal”
(MeSH), “aortic aneurysm repair,” “lower limb revascular-
ization,” “lower extremity revascularization,” “lower limb
bypass,” “lower extremity bypass,” and “infrainguinal
bypass” (Appendix, online only). A second level search
consisted of manual scrutiny of the bibliographic lists of
relevant articles and reviews. No language constraints exis-
ted. Only studies published in full text were considered. The
literature search and study selection was undertaken inde-
pendently by two reviewers (S.H. and S.H.). The selected
studies were sent to a third author (G.A.), who assessed their
suitability for inclusion and acted as an adjudicator in the
event of disagreement.Data collection and assessment of risk of bias. An elec-
tronic data extraction spreadsheet was created, pilot-tested in
ﬁve randomly selected articles, and adjusted accordingly. The
collected information was grouped in three broad categories:
1. Study-related data (ﬁrst author, year of publication,
country of origin of the corresponding author, jour-
nal in which the study was published, study design,
study size, clinical condition of the study participants,
type of intervention, duration of preinterventional
statin therapy, type and dose of statin);
2. Baseline demographic and clinical information of the
study populations (age, gender, smoking, hyperten-
sion, diabetes mellitus, coronary artery disease, and
cerebrovascular disease; and
3. Primary and secondary outcome data, as outlined
above.
The data collection was performed by two authors
(S.H., S.H.). No unpublished data were obtained.
The Cochrane collaboration’s tool was applied to assess
the risk of bias of the randomized trials.16 Brieﬂy, this tool
evaluates six main domains:
d Random sequence generation and allocation conceal-
ment (selection bias),
d Blinding of participants and personnel (performance
bias),
d Blinding of outcome assessment (detection bias),
d Incomplete outcome data (attrition bias),
d Selective reporting (reporting bias), and
d Other sources of bias.
We classiﬁed studies into low, unclear, and high risk of
bias for each individual domain.
For observational cohort or case control studies, we
used the Newcastle-Ottawa scale to assess the methodo-
logic quality and risk of bias.17 This scale uses a star system
with a maximum of nine stars, to evaluate a study in three
domains: the selection of the study groups, the compara-
bility of the groups, and the ascertainment of outcome of
interest. We judged studies that received a score of nine
stars to be at low risk of bias, studies that scored seven or
eight stars to be at medium risk, and those that scored
six or less to be at high risk of bias. Two authors (S.H.
and S.H.) assessed the methodologic quality of studies
included in this review.
Summary measures and synthesis. Statistical analysis
of the dichotomous variables was done using the odds ratio
(OR) as the summary statistic. We used random-effect
modeling by DerSimonian-Laird for analysis and reported
results in a forest plot with 95% conﬁdence intervals (CIs).
The ORs represented the odds of an adverse event
happening during the perioperative or peri-interventional
period (#30 days of intervention or during the hospital
stay) in participants taking a statin compared with those
taking a placebo or receiving no statin. An OR of <1 would
favor the statin-treated population. Heterogeneity among
Fig 1. Literature search strategy.
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Furthermore, we measured inconsistencyddeﬁned as the
percentage of total variation across studies due to
heterogeneitydof the effects of statin therapy, which has
the advantages that it does not inherently depend on the
number of studies and is accompanied by an uncertainty
interval. For each study, the effect by the inverse of its
standard error was plotted. Publication bias was assessed
visually by evaluating the symmetry of such funnel plots
and formally by using the Egger regression intercept.
We prespeciﬁed several additional analyses to assess the
robustness of our results and to explore potential sources of
heterogeneity. First, we tested the effect on the pooled OR
of removing one study at a time. Second, we repeated the
primary analysis using a ﬁxed-effects model. Third, the
treatment effects were examined according to study design
and type of intervention. We deemed an a level < .05 as
statistically signiﬁcant. Analyses were performed using Re-
view Manager 5.2 (The Nordic Cochrane Centre, The
Cochrane Collaboration, Copenhagen, Denmark) and
Comprehensive Meta-Analysis 2.0 software (Biostat, Eng-
lewood, NJ).
RESULTS
Literature search results. Searches of electronic infor-
mation sources identiﬁed 5513 reports. After screening titles
or abstracts, or both, and scrutinizing the retrieved full texts
of relevant articles, 24 studies were selected for data collec-
tion and analysis.18-41 Four randomized controlled trials and
20 observational studies, including 16 cohort and four case-
control studies, reported 23,536 patients. Of them, 8052
patients were allocated to or were receiving statin therapy at
the time of the vascular or endovascular intervention, and
the remaining 15,484 patients were assigned to no statintreatment. The selected randomized trials enrolled a total of
675 patients (355 patients in the statin group and another
320 patients in the no-statin group), with 22,861 patients
entered into our meta-analysis models coming from obser-
vational studies. A ﬂow diagram depicting the overall search
strategy is outlined in Fig 1.
Study characteristics and risk of bias within
studies. The individual study design, publication date,
clinical condition(s) of the study populations, and the
type and number of vascular or endovascular procedures
are presented in Table I. A wide range of vascular and
endovascular arterial reconstructive procedures was
noticed, including surgical or endovascular treatment of
peripheral arterial or aneurysmal disease affecting the lower
limbs, endarterectomy or stenting for carotid disease, and
open or endovascular repair of aortic aneurysm.
Baseline demographic and clinical characteristics,
including main atherosclerotic risk factors, are reported in
Table II. In general, patients who received statins tended
to have comorbid atherosclerotic conditions, including dia-
betes, hypertension, and coronary artery disease, at a higher
prevalence than patients receiving no statins, with several
studies reporting signiﬁcant differences between the two
groups. Interestingly, seven studies reported a signiﬁcantly
younger age in patients receiving statin therapy compared
with those not taking a statin, with the rest of the studies
not demonstrating age differences between the groups or
not reporting demographics.
The methodologic appraisal of the observational
studies is presented in Table III. The risk of bias in 17 of
the 20 observational studies was low (two studies) or mod-
erate (15 studies). Our assessments of the risk of bias of
randomized trials and support information for judgment
are reported in Table IV.
Table I. Summary characteristics of included studies
First author Year Country Journal Type of study
Clinical
presentation
Neilipovitz41 2012 Canada J Can Anesth RCT Aortic disease, infrainguinal
arterial disease
Le Manach39 2011 France Anesthesiology Prospective observational study Aneurysm or occlusive disease
of the aorta
Verzini40 2011 Italy J Vasc Surg Retrospective observational study Primary carotid stenosis
Desai35 2010 USA Arch Gerontol Geriatr Prospective observational study Carotid, abdominal aortic
and lower-limb arterial disease
Moulakakis37 2010 Germany Eur J Vasc Endovasc
Surg
Retrospective observational study Infrarenal AAA
McNally36 2010 USA J Vasc Surg Retrospective observational study Infrarenal AAA
Puato38 2010 Italy Stroke RCT Symptomatic carotid stenosis
$70%
Schouten34 2009 The Netherlands N Engl J Med RCT Carotid, abdominal aortic and
lower-limb arterial disease
Biccard33 2009 South Africa Cardiovasc J Afr Retrospective observational study NR
Welten32 2008 The Netherlands Nephrol Dial Transplant Retrospective observational studya Lower limb arterial disease,
AAA
Kor30 2008 USA J Cardiothorac Vasc
Anesth
Retrospective observational study Descending thoracic or
abdominal aortic disease
Schanzer31 2008 USA J Vasc Surg Prospective observational study Critical limb ischemia
Brooke29 2007 USA J Vasc Surg Retrospective observational studya Carotid disease
Leurs27 2006 USA Vascular Prospective observational study AAA
Schouten28 2006 The Netherlands Am J Cardiol Prospective observational study AAA
Gröschel26 2006 Germany Radiology Retrospective observational study Symptomatic carotid stenosis
McGirt23 2005 USA J Vasc Surg Retrospective observational study Carotid disease
Ward25 2005 USA Int J Cardiol Retrospective observational study PAD
Kennedy22 2005 Canada Stroke Retrospective observational study Symptomatic and asymptomatic
carotid disease
O’Neil-
Callahan24
2005 USA J Am Coll Cardiol Retrospective observational studya Carotid disease, aortic disease,
PAD
Durazzo20 2004 Brazil J Vasc Surg RCT Carotid disease, aortic disease,
PAD
Kertai21 2004 The Netherlands Eur J Vasc Endovasc
Surg
Retrospective observational study AAA
Abbruzzese19 2004 USA J Vasc Surg Retrospective observational study Infrainguinal arterial disease
Poldermans18 2003 USA Circulation Retrospective observational studya Carotid disease, aortic disease,
PAD
AAA, Abdominal aortic aneurysm; CAS, carotid angioplasty and stenting; CEA, carotid endarterectomy; EVAR, endovascular aortic aneurysm repair;NR, not
reported; PAD, peripheral arterial disease; RCT, randomized controlled trial; USA, United States of America.
aCase-control study.
bThree patients enrolled for infrainguinal arterial bypass and eventually underwent amputation.
cOutcomes of 30 of 43 enrolled patients were available.
dThere were 151 procedures in 150 patients, but data from 147 patients were analyzed.
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Procedure
Preinterventional
duration of statin therapy Type and dose of statin
Total number
of patients Statin
No
statin
Aortic surgery (n ¼ 19), infra-
inguinal revascularization (n ¼ 24)
7 days Atorvastatin 80 mg 30c 22 8
Infra-renal aortic reconstructive
surgery (n ¼ 1674)
>10 days Atorvastatin, or ﬂuvastatin, or pravastatin,
or rosuvastatin, or simvastatin
1674 880 794
CAS (n ¼ 1083) NR NR 1083 465 618
CEA (n ¼ 300), lower extremity
revascularization (n ¼ 179),
AAA repair (n ¼ 98)
NR NR 577 302 275
EVAR (n ¼ 127) >3 months Atorvastatin 40 mg, or ﬂuvastatin 40 mg,
or lovastatin 40 mg, or pravastatin
40 mg, or simvastatin 40 mg
127 58 69
Open AAA repair (n ¼ 228),
EVAR (n ¼ 173)
NR NR 401 181 220
CEA (n ¼ 58) 12 weeks 6 2 days Atorvastatin 10 mg or atorvastatin
80 mg
58 39 19
Carotid artery surgery (n ¼ 69),
open (n ¼ 112) and endovascular
(n ¼ 124) abdominal aortic surgery,
lower-limb arterial surgery (n ¼ 192)
37 days Fluvastatin 80 mg 497 250 247
NR NR NR 114 31 83
Lower limb arterial reconstructive
surgery (n ¼ 913), AAA repair
(n ¼ 1031)
NR NR 1944 515 1429
Open repair of the descending
thoracic (n ¼ 21) or abdominal
aortic disease (n ¼ 130)
NR NR 147d 85 62
Infrainguinal bypass surgery with
autogenous vein (n ¼ 1404)
NR NR 1404 636 768
CEA (n ¼ 1561) NR NR 1561 654 907
EVAR (n ¼ 5892) NR NR 5892 731 5161
Elective AAA repair requiring
suprarenal clamping (n ¼ 77)
NR Simvastatin, or atorvastatin, or
ﬂuvastatin, or pravastatin
77 28 49
CAS (n ¼ 180) At least 1 week Atorvastatin 10-40 mg, or simvastatin
40 mg, or pravastatin 10-40 mg, or
cerivastatin 0.3 mg, or lovastatin 40 mg
180 53 127
CEA (n ¼ 1566) At least 1 week Atorvastatin 20 6 10 mg, or simvastatin
20 6 10 mg, or pravastatin
30 6 10 mg, or lovastatin
30 6 10 mg, or ﬂuvastatin
30 6 10 mg
1566 657 909
Infrainguinal arterial bypass surgery
(n ¼ 446)
NR NR 446 72 374
CEA (n ¼ 3283) NR NR 3283 1480 1803
CEA (n ¼ 364), aortic surgery
(aortoiliac bypass, aneurysm, or
dissection repair) (n ¼ 177), lower
extremity revascularization (n ¼ 622)
NR NR 1163 526 637
Elective noncardiac arterial vascular
surgery: aortic repair (n ¼ 56),
infrainguinal arterial bypass (n ¼ 23),
CEA (n ¼ 11)b
45 days Atorvastatin 20 mg 90 44 46
Elective open infrarenal abdominal
aortic surgery (n ¼ 570)
at least 1-3 months Simvastatin, or atorvastatin, or
pravastatin, or cerivastatin,
or ﬂuvastatin
570 162 408
Infrainguinal arterial reconstructions
using autogenous saphenous vein
(n ¼ 172)
NR Atorvastatin, or cerivastatin, or
lovastatin, or pravastatin, or
simvastatin
172 88 84
AAA repair (n ¼ 408), lower
extremity revascularization
(n ¼ 51), CEA (n ¼ 21)
1 to 22 months NR 480 93 387
Table I. Continued.
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Table II. Baseline demographic and clinical characteristics
First author Mean age, years Male gender, % Smoking, % Diabetes, % Hypertension, % CAD, % CVD, %
Neilipovitz41 NR NR NR NR NR NR NR
Le Manach39 67 vs 67
(P ¼ .29)
87 vs 88
(P ¼ .55)
NR 16 vs 11
(P ¼ .01)
70 vs 54
(P ¼ .001)
48 vs 22
(P ¼ .001)
NR
Verzini40 70.15 vs 72.5
(P < .0001)
69.3 vs 72.4
(P ¼ .279)
NR 31.3 vs 30.2
(P ¼ .690)
86 vs 81.8
(P ¼ .069)
42.3 vs 32.5
(P ¼ .001)
22.5 vs 26.3
(P ¼ .156)
Desai35 74 vs 73 (NS) 66 vs 65 (NS) 29 vs 28 (NS) 36 vs 29 (NS) 82 vs 77 (NS) 65 vs 58 (NS) 17 vs 23 (NS)
Moulakakis37 70.6 vs 72.3
(P > .05)
88 vs 88.5
(P > .05)
62 vs 59
(P > .05)
18.5 vs 11
(P > .05)
48 vs 56
(P > .05)
55 vs 53
(P > .05)
21 vs 19.5
(P > .05)
McNally36 NR NR NR NR NR NR NR
Puato38 NR NR NR NR NR NR NR
Schouten34 66.0 vs 65.8 77.6 vs 72.1 NR 22 vs 17 56.8 vs 57.9 29.2 vs 26.7a 30 vs 26.7
Biccard33 66 vs 62.5
(P ¼ .08)
NR NR 45.2 vs 32.5
(P ¼ .27)
NR 93.5 vs 62.7
(P ¼ .001)
NR
Welten32 NR NR NR NR NR NR NR
Kor30 71 vs 71
(P ¼ .71)
81 vs 69
(P ¼ .1)
NR 15 vs 13
(P ¼ .77)
85 vs 69
(P ¼ .02)
62 vs 40
(P < .01)
28 vs 18
(P ¼ .14)
Schanzer31 68.5 vs
68.5 (NS)
61.2 vs
65.9 (NS)
73.9 vs 73.7 (NS) 72 vs 57.6
(P < .05)
85.4 vs 78.5
(P < .05)
52.7 vs 32.7
(P < .05)
NR
Brooke29 NR NR NR NR NR NR NR
Leurs27 70.1 vs 72.6
(P < .0001)
94.9 vs
94.0 (NS)
23.5 vs
23.8 (NS)
17.4 vs 11.6
(P < .0001)
73.0 vs 62.7
(P < .0001)
69.6 vs 59.3
(P < .0001)
NR
Schouten28 68 vs 70
(P ¼ .37)
68 vs 77
(P ¼ .41)
NR 4 vs 6 (P ¼ 1.0) 36 vs 51
(P ¼ .24)
29 vs 37
(P ¼ .62)a
11 vs 18
(P ¼ .52)
Gröschel26 67 vs 70
(P < .05)
75 vs 70 32 vs 28 26 vs 26 89 vs 72
(P < .05)
38 vs 18
(P < .01)
34 vs 29
McGirt23 70 vs 74
(P ¼ .001)
66 vs 61
(P ¼ .020)
30 vs 19
(P ¼ .001)
28 vs 24
(P ¼ .075)
85 vs 75
(P ¼ .001)
57 vs 43
(P < .001)
11 vs 17
(P ¼ .001)
Ward25 66 vs 67 (NS) 45 vs 52 (NS) 50 vs
54 (NS)
56 vs 53 (NS) 78 vs 75 (NS) 67 vs 58 (NS) NR
Kennedy22 NR NR NR NR NR NR NR
O’Neil-
Callahan24
NR NR NR NR NR NR NR
Durazzo20 65.92 vs 68.38
(P ¼ .208)
80 vs 78
(P ¼ 1.000)
12 vs 22
(P ¼ .596)
18 vs 16
(P ¼ 1.000)
76 vs 70
(P ¼ .653)
30 vs 28
(P ¼ 1.000)a
NR
Kertai21 65.1 vs 70.5
(P < .001)
78 vs 88
(P ¼ .002)
30 vs 32
(P ¼ .7)
9 vs 5 (P ¼ .2) 47 vs 49
(P ¼ .8)
38 vs 19
(P < .001)a
13 vs 16
(P ¼ .4)
Abbruzzese19 67 vs 70
(P < .04)
61 vs 56
(P ¼ .47)
19 vs 21
(P ¼ .73)
66 vs 55
(P ¼ .14)
61 vs 71
(P ¼ .16)
67 vs 42
(P < .01)
15 vs 17
(P ¼ .73)
Poldermans18 NR NR NR NR NR NR NR
CAD, Coronary artery disease; CVD, cerebrovascular disease; NR, not reported; NS, nonsigniﬁcant.
aPrevious myocardial infarction.
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outcome parameters are depicted in Fig 2.
All-cause mortality. All-cause mortality was reported in
19 studies (18,770 patients). Patients receiving a statin at the
time of intervention had a lower mortality rate (1.5%) than
patients not prescribed statin therapy (3.5%; OR, 0.54; 95%
CI, 0.38-0.78; P ¼ .001). Low heterogeneity among the
selected studies was identiﬁed (I2 ¼ 43%, P ¼ .04), and
the likelihood of publication bias was low (P ¼ .733).
Cardiovascular mortality. Eight studies (5319 pa-
tients) reported cardiovascular mortality and found no sig-
niﬁcant difference between the groups (2.8% vs 2.9%; OR,
0.82; 95% CI, 0.41-1.63; P ¼ .56). Moderate heterogene-
ity among the studies existed (I2 ¼ 55%, P ¼ .08), and the
possibility of publication bias was low (P ¼ .473).
Myocardial infarction. The incidence of myocardial
infarction within the perioperative period was reported by
13 studies (7937 patients). Myocardial infarction was lesslikely to occur in patients receiving a statin at the time of
intervention than in those not taking a statin (2.3% vs
3.4%; OR, 0.62; 95% CI, 0.45-0.87; P ¼ .005). Heteroge-
neity among the studies was low (I2 ¼ 12%, P ¼ .33), and
the likelihood of publication bias was low (P ¼ .615).
Stroke. Perioperative or peri-interventional stroke
ﬁgures were reported in 12 studies (10,640 patients). The
incidence of stroke was signiﬁcantly lower in the statin
group (5.4% vs 9%; OR, 0.51; 95% CI, 0.39-0.67; P <
.001). The heterogeneity among the studies was low (I2 ¼
7%, P ¼ .38), and the possibility of publication bias was not
signiﬁcant (P ¼ .219).
Myocardial infarction/stroke/death. Seven studies
reported the composite of myocardial infarction, stroke,
and death (5650 patients), the incidence of which was
signiﬁcantly lower in patients receiving statins (2.4% vs
5.3%; OR, 0.45; 95% CI, 0.29-0.70; P ¼ .0004). No sig-
niﬁcant heterogeneity among the studies existed (I2 ¼
Table III. Methodologic quality of the observational studies assessed with the Newcastle-Ottawa Scale
First author
Representativeness
of the exposed
cohort
Selection of
the non-
exposed
cohort
Ascertainment
of exposure
Demonstration
that outcome
of interest was
not present at
start of study
Comparability
of cohorts on
the basis of
the design or
analysis
Assessment
of outcome
Was follow-up
long enough
for outcomes
to occur?
Adequacy
of follow-up
of cohorts
Total
score
Le Manach39 * * * * ** * * * 9
Verzini40 * * * ** * * * 8
Desai35 * * * * * * * 7
Moulakakis37 * * * * * * 6
McNally36 * * * * ** * * * 9
Biccard33 * * * ** * * 7
Welten32 * * * ** * * 8
Kor30 * * * ** * * * 8
Schanzer31 * * * ** * * 7
Brooke29 * * * ** * * * 8
Leurs27 * * * ** * * * 8
Schouten28 * * * * * * 6
Gröschel26 * * * ** * * * 8
McGirt23 * * * ** * * * 8
Ward25 * * * ** * * * 8
Kennedy22 * * * ** * * * 8
O’Neil-
Callahan24
* * * ** * * * 8
Kertai21 * * * ** * * * 8
Abbruzzese19 * * * * * * 6
Poldermans18 * * * ** * * * 8
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not signiﬁcant (P ¼ .09).
Renal impairment. The incidence of peri-interventional
renal impairment was reported in six studies (4465 patients).
The authors used several different deﬁnitions of renal
impairment: Le Manach et al39 deﬁned postoperative renal
failure as an increase of 30% in the postoperative plasma
creatinine concentration or the requirement for post-
operative hemodialysis in patients who did not require it
preoperatively; similarly, Moulakakis et al37 and McNally
et al36 deﬁned renal impairment as increased serum creati-
nine requiring hemodialysis, whereas Kor et al30 deﬁned
acute renal failure by the glomerular ﬁltration rate criteria
proposed by the Acute Dialysis Quality Initiative group.
Welten et al32 deﬁned acute kidney failure as a decrease of
>10% in creatinine clearance compared with the baseline
value. No signiﬁcant differences between the groups were
identiﬁed (15.6% vs 21.7%, OR, 0.90; 95% CI, 0.58-1.39,
P ¼ .63). Moderate heterogeneity among the studies was
found (I2 ¼ 59%, P ¼ .05), and the likelihood of publica-
tion bias low (P ¼ .807).
Sensitivity analyses. To check whether individual
studies unduly inﬂuenced overall results, the analyses
were repeated, excluding each study one at a time; no
signiﬁcant discrepancies in the outcomes were identiﬁed.
The analyses were also repeated using ﬁxed-effects
models to assess the inﬂuence of statistical heterogene-
ity on the overall ﬁndings by comparing the result with
the more conservative random-effects model. No
changes in outcomes were noticed when ﬁxed-effects or
random-effects models were applied. Similarly, statisticalmodels calculating risk rather than ORs did not alter the
results.
Separate meta-analysis models were created to
include randomized trials only (Supplementary Table I,
online only). Pooled analysis revealed no difference in
all-cause mortality between the statin and the no-statin
group (OR, 0.57; 95% CI, 0.27-1.17; P ¼ .13). Cardio-
vascular mortality was reported in two trials, analysis of
which found no signiﬁcant differences between the
groups (OR, 0.49; 95% CI, 0.14-1.63; P ¼ .24). Pooled
results from four trials showed a signiﬁcantly lower inci-
dence of peri-interventional myocardial infarction in pa-
tients assigned to statin therapy (OR, 0.44; 95% CI,
0.22-0.91; P ¼ .03), but no difference in the peri-
interventional stroke rate (OR, 0.33; 95% CI, 0.06-
1.74; P ¼ .19). Two trials reported the composite of
myocardial infarction/stroke/death, analysis of which
found no difference between the groups (OR, 0.47;
95% CI, 0.03-8.01; P ¼ .60). None of the randomized
trials reported renal outcomes.
Six studies comprised only patients with carotid disease
undergoing carotid intervention (carotid endarterectomy
or carotid angioplasty and stenting). Pooled analyses of
ﬁve of them showed that the all-cause mortality was signif-
icantly lower in patients receiving statin treatment (OR,
0.32; 95% CI, 0.15-0.65; P ¼ .002). The incidence of
myocardial infarction (analysis of four studies) was not
different between the groups (OR, 0.61; 95% CI,
0.29-1.28; P ¼ .19), whereas the peri-interventional stroke
rate (analysis of six studies: OR, 0.46; 95% CI, 0.29-0.74;
P ¼ .001) and the composite of myocardial infarction/
Table IV. Assessment of risk of bias of the randomized trials using the Cochrane Collaboration’s tool
First author Methodological item
Authors’
judgment Support for judgment
Neilipovitz41 Random sequence generation
(selection bias)
Low risk A computer-generated random numbers table was created
by an investigator not involved with bedside care or
outcome assessment. Randomization was blocked in
groups of six and stratiﬁed by procedure.
Allocation concealment (selection bias) Low risk The study medications were prepared in the form of
identical capsules in similar, sequentially numbered
containers by a pharmacist, who was not involved in the
study.
Blinding of participants and personnel
(performance bias)
Low risk Double-blind trial. All participants, care providers,
investigators, and research personnel remained
blinded to intervention throughout the study.
Blinding of outcome assessment
(detection bias)
Low risk Extensive blinding of participants, care providers,
investigators, and research personnel throughout
the study with regards to outcome assessment.
Incomplete outcome data (attrition bias) High risk Inconsistency in numbers reported by the study. Outcomes
of 31 of a total of 43 patients were
obtained from author by Sanders et al.
Selective outcome reporting (reporting bias) Low risk All outcomes date reported, except length of stay.
Other potential threats to validity Unclear risk Baseline characteristics of patients with outcome data were
not similar between groups.
Puato38 Random sequence generation (selection bias) Unclear risk No details of randomization.
Allocation concealment (selection bias) Unclear risk No information given.
Blinding of participants and personnel
(performance bias)
High risk Single-blind trial (only investigators were blinded
to the treatment); no further information is given about
the blinding process.
Blinding of outcome assessment
(detection bias)
High risk Single-blind trial (only investigators were blinded
to the treatment); no further information is given about
the blinding process.
Incomplete outcome data (attrition bias) Low risk Only 1 patient in the intervention group and 1
patient in the control group were lost to follow-up.
Selective outcome reporting (reporting bias) Low risk Outcome data were supplied when requested.
Other potential threats to validity Low risk Similar baseline characteristics in both groups.
Schouten34 Random sequence generation (selection bias) Low risk A computer-generated randomization list was
obtained by the study statistician.
Allocation concealment (selection bias) Low risk Independent pharmacists dispensed either active study
drugs or placebo according to the randomization list.
Blinding of participants and personnel
(performance bias)
Low risk Double-blind trial; study personnel and patients were
unaware of the group assignments for the duration of the
study.
Blinding of outcome assessment
(detection bias)
Low risk The study outcomes were analyzed by two experienced
clinicians who were unaware
of the patient’s clinical data.
Incomplete outcome data (attrition bias) Low risk 19 of 250 patients in the intervention group and 19 of 247
patients in the intervention group discontinued or did
not take the study drug.
Selective outcome reporting (reporting bias) Low risk All outcome data reported.
Other potential threats to validity Low risk Similar baseline characteristics in both groups.
Durazzo20 Random sequence generation (selection bias) Low risk A computer algorithm was used in the randomization.
Allocation concealment (selection bias) Low risk No information given in the paper; addition information
from author presented by Sanders et al as “Adequate
allocation concealment was obtained using sequentially
numbered and sealed opaque envelopes and
randomization was performed by the pharmacy of the
hospital.”
Blinding of participants and personnel
(performance bias)
Low risk Double-blind trial; all clinical and study investigators were
blinded to study group assignments throughout all
phases of the trial
Blinding of outcome assessment
(detection bias)
Low risk All data were collected by study investigators, and were
analyzed by a cardiovascular endpoint committee, all
being unaware of patient group assignment.
Incomplete outcome data (attrition bias) Low risk The surgical procedure was cancelled in 6 of 50 patients in
the intervention group and 4 of 50 patients in the control
group.
Selective outcome reporting (reporting bias) Low risk All outcome data reported.
Other potential threats to validity Low risk Similar baseline characteristics in both groups.
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CI, 0.26-0.88, P ¼ .02) was signiﬁcantly lower in the
statin group. No sufﬁcient data for cardiovascular mortality
and renal impairment in patients undergoing carotid inter-
vention were available to calculate pooled outcome esti-
mates (Supplementary Table II, online only).
Two studies included patients undergoing carotid an-
gioplasty and stenting. Sensitivity analyses excluding these
two studies, which have a low mortality weight (1%) and
a high stroke weight (11%), and analyses excluding all
studies reporting carotid interventions did not alter the
pooled outcome estimates.
Five studies reported only patients undergoing open or
endovascular aortic aneurysm repair (Supplementary
Table III, online only). Data for all-cause mortality were
available from four studies, pooled analysis of which
revealed a trend toward improved outcome in patients tak-
ing a statin (OR, 0.29; 95% CI, 0.08-1.11; P ¼ .07). No
data for cardiovascular mortality or stroke were available.
Myocardial infarction rates were reported in one study
only, which found no difference between the groups (OR,
0.20; 95% CI, 0.02-1.66; P ¼ .14). Another study that re-
ported the composite of myocardial infarction/stroke/
death found improved outcome in patients receiving statins
(OR, 0.31; 95% CI, 0.13-0.74, P¼ .009). Two studies pro-
vided data for analysis of renal outcomes and found no dif-
ferences in the incidence of peri-interventional renal
impairment between the statin and the no-statin group
(OR, 0.17; 95% CI, 0.02-1.39; P ¼ .10).
DISCUSSION
A recently published Cochrane review pooled results
from three trials, with a total of 178 participants, for mor-
tality and nonfatal event outcomes.13 Analyses failed to
demonstrate beneﬁcial effects of perioperative use of statins
in vascular surgery. In view of the inconclusive evidence
provided by this review, we undertook a comprehensive
literature review and analysis and identiﬁed all relevant re-
ports, either randomized trials or observational studies,
investigating the effects of perioperative statin use in
vascular and endovascular surgery. Our analysis of four ran-
domized trials and 20 observational studies, reporting
w23,500 patients undergoing vascular or endovascular
surgery, found that the perioperative administration of sta-
tins is beneﬁcial. For most of the primary and secondary
outcome parameters, including all-cause mortality, myocar-
dial infarction, stroke, and the composite of myocardial
infarction/stroke/death, a decreased risk associated with
peri-interventional statin therapy was demonstrated. In
the observational studies, patients already receiving statins
could represent better management of coexisting medical
comorbidities. This in turn could account for the improved
all-cause mortality. It is possible that the beneﬁcial effects
seen with statins are actually the result of an overall more
comprehensive and aggressive medical regimen and
possibly a result of greater compliance with that regimen.
A relatively small number of studies reporting a rela-
tively limited number of patients provided relevantoutcome data for cardiovascular mortality, which might
explain why no risk difference associated with statin use
was identiﬁed for this outcome parameter. Furthermore,
inconsistency in the deﬁnition of cardiovascular death
existed among the studies, with some of the studies not
providing a deﬁnition. It might be that cardiovascular mor-
tality is hidden in total mortality and no sufﬁcient data are
available to draw robust ﬁgures. Two reports provided 80%
of the weight for this outcome.31,39 In both studies, dia-
betes and coronary artery disease were more prevalent in
statin patients, which is another possible explanation for
the lack of signiﬁcant difference between the groups.
A comprehensive literature search identiﬁed limited
high-level evidence deriving from well-designed random-
ized controlled trials. Statin-naïve patients enrolled in
such trials (675 patients) constitute only a small proportion
of the total meta-analysis population. Almost all partici-
pants come from prospective or retrospective observational
studies, which compromises the validity of our ﬁndings and
introduces bias to the reported outcomes. To circumvent
such methodologic constraints, sensitivity analyses were
undertaken, and meta-analysis models including random-
ized trials only were constructed. Such analyses revealed a
signiﬁcant reduction in the peri-interventional risk of
myocardial infarction associated with statin administration.
A clinically relevant trend toward reduced all-cause mortal-
ity, cardiovascular mortality, stroke, and the composite of
myocardial infarction, stroke, and death was found but
did not reach our threshold of statistical signiﬁcance. The
discrepancy between the outcomes of analysis of the total
population and those of the randomized trials might be
explained by the small numbers of events in the latter,
resulting in no statistical risk reduction associated with
statin therapy being identiﬁed.
The mechanisms through which statins confer their
postulated protective cardiovascular and cerebrovascular
effects remain uncertain. Clinical and basic research
experimental studies have demonstrated that the effects
of statins extend beyond their lipid-lowering action.42-44
Such effects comprise anti-inﬂammatory and immuno-
modulation properties, enhancement of endothelial
function, antithrombotic effects, and atherosclerotic pla-
que stabilization.
Adverse perioperative cardiovascular events in patients
undergoing vascular surgery, such as myocardial infarction
and death from cardiac causes, are related to the high prev-
alence of underlying coronary artery disease in these pa-
tients. Apart from an assumed dynamic imbalance between
myocardial oxygen supply and demand precipitated by peri-
operative hypotension, the surgical stress elicits an inﬂamma-
tory process that results in catecholamine release, platelet
activation and aggregation, reduced ﬁbrinolytic activity,
and vasospasm. Resultant plaque instability, thrombus for-
mation, and vessel occlusion constitute potential underlying
pathophysiologic mechanisms for cardiovascular complica-
tions in patients undergoing noncardiac vascular sur-
gery.45-47 One may speculate that statins affect some or all
of these mechanisms through their pleiotropic properties,
Fig 2. Forest plots of comparison of (a) all-cause mortality, (b) cardiovascular mortality, (c) myocardial infarction, (d)
stroke, (e) composite of death/myocardial infarction/stroke; and (f) renal impairment. The solid squares denote the
odds ratios (ORs), the horizontal lines represent the 95% conﬁdence intervals (CIs), and the diamond denotes the
pooled OR. M-H, Mantel-Haenszel test.
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strated in our analysis. Statins may attenuate coronary artery
plaque inﬂammation and inﬂuence plaque stability, thereby
reducing myocardial ischemia and subsequent myocardial
damage.
Interestingly, we found that peri-interventional statin
therapy reduced the incidence of adverse cerebrovascular
events in patients undergoing carotid and other noncardiac
arterial reconstruction. This result is consistent with ﬁnd-
ings of experimental studies, supporting that statins are
neuroprotectants, improve cerebrovascular autoregulation,
attenuate neuroinﬂammatory response, and stabilize arte-
rial plaques.48,49 Statins’ antioxidant activity, antithrom-
botic properties, and effects on cerebral vasomotor toneand vascular endothelium might protect the brain during
carotid interventions. Furthermore, similar to the effects
in the coronary circulation, statin therapy taken during
the perioperative period may stabilize carotid plaques,
disruption of which might otherwise lead to cerebral embo-
lization and peri-interventional stroke.50
Pooled analysis of studies reporting perioperative acute
kidney injury did not demonstrate advantageous effects asso-
ciated with statin therapy. Our inconclusive results might be
because the potential mechanisms of renal impairment vary
among different vascular and endovascular interventions.
Such mechanisms are usually multifactorial, including peri-
operative hypotension and hypovolemia, embolization into
the renal arteries during aortic manipulation, nephrotoxicity
Fig 2. Continued.
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tory response. The limited available information and the
heterogenous nature of our meta-analysis population,
comprising diverse procedures and vascular disease, do notallow us to conclude about the role of statins in protection
of renal function perioperatively.
How long statin therapy should be initiated before the
vascular intervention to achieve its beneﬁcial effects is
Fig 2. Continued.
JOURNAL OF VASCULAR SURGERY
530 Antoniou et al February 2015unknown. Inconsistency in the duration of statin adminis-
tration existed among the studies included in our analysis.
This varied from 1 week to 3 months. Even though the ef-
fect of such heterogeneity cannot be estimated, it has been
recognized that treatment given for >5 days reaches a
plateau with regard to the vascular pleiotropic effects of sta-
tins.51 There is insufﬁcient information to support the initi-
ation of statin treatment as a risk-reduction strategy in
urgent and emergency vascular procedures. In addition,
concerns have been postulated regarding the necessity of
treatment interruption when oral administration is not
feasible because of the potential diminished beneﬁt when
absorption in the postoperative period is suboptimal. The
effect of other medications, such as antiplatelet agents
and b-blockers, on the beneﬁcial effects of statin therapy
on perioperative outcomes needs to be investigated.
We decided not to perform pooled analysis of adverse
effects associated with perioperative statin therapy because
of the inconsistency in ascertainment across studies.
Whether the beneﬁts of peri-interventional statin therapy
outweighs potential risks remains unknown. The incidence
of adverse clinical muscle syndromes and hepatic damage
appears to be low.52
CONCLUSIONS
Implications for clinical practice. Our analysis has
demonstrated that perioperative statin administration
improves outcomes, as indicated by decreased mortality,
cardiac and cerebrovascular events. Limited information
derives from well-designed randomized controlled trials
investigating effects in statin-naïve patients. Statin therapy
should be applied as integral part of the pharmacologic
optimization strategy for secondary prevention in patients
undergoing vascular or endovascular surgery. This strategy
might have cost-effective implications in clinical practice
and confer beneﬁcial effects on resource utilization.
Implications for future research. Except in patients
with aortic aneurysm, in whom there is no compelling ev-
idence for statin therapy, all patients diagnosed with pe-
ripheral arterial disease should take a statin. Such
widespread use of statins makes further randomized trials
enrolling statin-naïve patients impractical. Reporting stan-
dards on perioperative cardiovascular risk reduction,including mortality, stroke, myocardial infarction, and car-
diovascular mortality, should be applied in future studies.
The optimal dosage and timing of statin therapy in patients
undergoing vascular and endovascular interventions remain
to be deﬁned. The safety of statin treatment in the peri-
interventional period has not been adequately evaluated.
Speciﬁc mechanisms of protection in vascular and endo-
vascular interventions need to be elucidated in both
experimental and clinical studies.
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(MEDLINE, PubMed)
1. hydroxymethylglutaryl-CoA reductase inhibitors
(MeSH)
2. HMG-CoA reductase inhibitors
3. statin
4. statins
5. lipid-lowering therapy
6. lipid-lowering treatment
7. lipid pharmacotherapy
8. non-cardiac vascular surgery
9. vascular surgery
10. vascular surgical procedures (MeSH)Supplementary Table II (online only). Meta-analysis of stud
interventions
Outcome Studies, No.
All-cause mortality 5
Cardiovascular mortality NR
Myocardial infarction 4
Stroke 6
Composite myocardial infarction/stroke/death 4
Renal impairment NR
CI, Conﬁdence interval; NR, not reported; OR, odds ratio.
aTest for heterogeneity.
Supplementary Table I (online only). Meta-analysis of rand
Outcome Trials, No.
All-cause mortality 4
Cardiovascular mortality 2
Myocardial infarction 4
Stroke 4
Composite myocardial infarction/stroke/death 2
Renal impairment NR
CI, Conﬁdence interval; NA, not applicable; NR, not reported; OR, odds ratio.
aTest for heterogeneity.
Supplementary Table III (online only). Meta-analysis of stu
aneurysm repair
Outcome Studies (No.)
All-cause mortality 4
Cardiovascular mortality NR
Myocardial infarction 1
Stroke NR
Composite myocardial infarction/stroke/death 1
Renal impairment 2
CI, Conﬁdence interval; NA, not applicable; NR, not reported; OR, odds ratio.
aTest for heterogeneity.11. peripheral arterial disease (MeSH)
12. endarterectomy, carotid (MeSH)
13. aortic aneurysm, abdominal (MeSH)
14. aortic aneurysm repair
15. lower limb revascularization
16. lower extremity revascularization
17. lower limb bypass
18. lower extremity bypass
19. infrainguinal bypass
20. 1 or 2 or 3 or 4 or 5 or 6 or 7
21. 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17
or 18 or 19
22. 20 and 21
MeSH, Medical subject heading.ies reporting outcomes in patients undergoing carotid
Patients, No. OR (95% CI) P value I2a, %
6170 0.32 (0.15-0.65) .002 0
NR NR NR NR
2887 0.61 (0.29-1.28) .19 0
7731 0.46 (0.29-0.74) .001 47
4604 0.48 (0.26-0.88) .02 34
NR NR NR NR
omized controlled trials
Patients, No. OR (95% CI) P value I2a, %
675 0.57 (0.27-1.17) .13 0
527 0.49 (0.14-1.63) .24 NA
675 0.44 (0.22-0.91) .03 0
675 0.33 (0.06-1.74) .19 0
88 0.47 (0.03-8.01) .60 NA
NR NR NR NR
dies reporting outcomes in patients undergoing aortic
Patients (No.) OR (95% CI) P value I2a (%)
6497 0.29 (0.08-1.11) .07 45
NR NR NR NR
401 0.20 (0.02-1.66) .14 NA
NR NR NR NR
570 0.31 (0.13-0.74) .009 NA
528 0.17 (0.02-1.39) .10 NA
